Two major pharmaceutical companies developing advanced-stage R&D on Alzheimer’s disease have just pulled the plug on their research. The reason why their approach to Alzheimer’s, Aducanumab, failed is because it didn’t account for a factor that is central
to R&D conducted by biotechnology Company ProMIS Neurosciences Inc.
(TSX:PMN, OTCQB:ARFXF, Forum).
Preclinical studies show the Company's lead antibody candidate, PMN310,
demonstrates a high degree of binding to toxic oligomers from Alzheimer's disease brains without binding to plaque or other non-toxic forms of the toxic oligomer form of
amyloid beta (Aβ).
Not only has an important competitor dropped out of the race to find an Alzheimer’s
treatment, the reason for failure suggests that ProMis is on the right track with its own
Stockhouse is joined by Company President and CEO, Dr. Elliot Goldstein to learn
more about ProMIS’ research and potential to combat Alzheimer’s Disease.
StockTalk Podcast Exclusive: Investing Guru Rick Rule
Stockhouse Podcast Exclusive: The Incomparable Bruce Linton
PODCAST: 1933 Industries
PODCAST: Stockhouse CEO Interview Series with the CSE's Richard Carleton
PODCAST: Stockhouse Hosts Expert Panel on Battery Metals
Podcast #71 Grown Rogue CEO Obie Strickler
FinCanna Update Call
Stockhouse Media Interview with Colin Fisher
Rick Rule Talks Investment Opportunities: Good Value and Bad Ideas
Podcast #69 Nighthawk Gold Corp
Frank Holmes Talks Markets
Podcast #68 Granada Gold Mine Inc.
Blockchain 101 Podcast - Eps 6 - Peter McCormack
Podcast #67 Bluebird Battery Metals
Podcast #66 Blockstrain Technology Corp
Blockchain 101 Podcast - Eps 5 - Chase Cedar
Podcast #65 Osisko Gold Royalties (2)
Podcast #64 MedMen Enterprises
Blockchain 101 Podcast - Eps 4 - Jonathan Hamel
The Dave Ramsey Show
The Tim Ferriss Show
The BiggerPockets Real Estate Investing Podcast
Masters in Business
The Chris Hogan Show
Code and preview